BridgeBio Pharma (BBIO) Superinvestor holders
22 of the superinvestors we track hold BridgeBio Pharma (BBIO) in their latest 13F filings, $2.7B in total.
Summary
The largest holder is Tom Steyer (Farallon Capital Management LLC), with $800M, 4.7% of the portfolio.
In their latest quarter: 2 opened a new position, 11 added, 7 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Tom Steyer Farallon Capital Management LLC |
Added | 10,743,063 | $800M | 4.7% | Q2 2026 |
| Andreas Halvorsen Viking Global Investors |
Trimmed | 9,949,219 | $741M | 2.1% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Added | 4,722,185 | $352M | 0.3% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 3,633,007 | $271M | 0.2% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
New position | 1,525,782 | $114M | 0.2% | Q2 2026 |
| PRIMECAP Management PRIMECAP Management Co |
Added | 1,015,980 | $76M | 0.0% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Added | 993,103 | $74M | 0.1% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Added | 856,846 | $64M | 0.1% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 760,977 | $57M | 0.1% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
Added | 448,143 | $33M | 0.1% | Q2 2026 |
| Ken Fisher Fisher Investments |
Added | 348,675 | $23M | 0.0% | Q3 2026 |
| Paul Marshall Marshall Wace |
Trimmed | 275,516 | $21M | 0.0% | Q2 2026 |
| Chuck Royce Royce Investment Partners |
Held | 218,487 | $14M | 0.1% | Q3 2026 |
| Cliff Asness AQR Capital Management |
Added | 166,949 | $12M | 0.0% | Q2 2026 |
| WCM Investment Management | Trimmed | 165,133 | $12M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
Added | 155,727 | $12M | 0.2% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
New position | 77,170 | $6M | 0.0% | Q2 2026 |
| Man Group Man Group plc |
Trimmed | 27,526 | $2M | 0.0% | Q2 2026 |
| Alger Fred Alger Management |
Trimmed | 22,170 | $2M | 0.0% | Q2 2026 |
| Didric Cederholm Lion Point Capital |
Held | 5,000 | $372,400 | 1.8% | Q2 2026 |
| Dan Davidowitz Polen Capital Management |
Trimmed | 4,002 | $298,069 | 0.0% | Q2 2026 |
| Alec Litowitz Magnetar Capital |
Added | 3,740 | $278,555 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 23 |
| Q1 2026 | 23 |
| Q4 2025 | 22 |
| Q3 2025 | 20 |
| Q2 2025 | 20 |
| Q1 2025 | 17 |
| Q4 2024 | 13 |
| Q3 2024 | 16 |
Questions about BridgeBio Pharma
Which superinvestors own BridgeBio Pharma?
22 of the superinvestors we track hold BridgeBio Pharma (BBIO) in their latest 13F filings, $2.7B in total. Tom Steyer, Andreas Halvorsen, Two Sigma, David Shaw, Steve Cohen, PRIMECAP Management.
Who is the largest superinvestor holder of BBIO?
The largest holder is Tom Steyer (Farallon Capital Management LLC), with $800M, 4.7% of the portfolio.
From BridgeBio Pharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.